Indian Panel Nudges Eisai Towards Phase IV Compliance For Halaven
Executive Summary
Eisai’s request to forego Phase IV studies for its anticancer, Halaven, has been turned down by an Indian expert panel, which has reminded the Japanese company of the conditional marketing authorization previously granted for the product. Eisai, for its part, now says it will follow the “necessary requirements” set out by the Indian regulator.
You may also be interested in...
Why Pharma Doesn't Always Keep Phase IV Promises In India
Are drug firms being lax when it comes to Phase IV studies in markets like India or are certain arbitrarily determined regulatory requirements largely to blame? Scrip delves into the issue.
Keytruda’s Catch-22 Situation In India Amid Compliance Questions
Merck & Co’s immuno-oncology therapy Keytruda appears be facing a rather paradoxical situation in India, after an expert panel noted that the US multinational had failed to comply with Phase IV study requirements pertaining to the product in the country.
Eisai Fortifies Play With India-Specific Priced Fycompa
Eisai expects products like Fycompa and Lenvima, backed by innovative price planks pivoted around improving patient access, to intensify growth in India. Fycompa now debuts at a sub-$1 per day pricing in India.